LivaNova/LIVN

$52.99

-1.99%
-
1D1W1MYTD1YMAX

About LivaNova

LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.

Ticker

LIVN

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

William Kozy

Employees

2,900

Headquarters

London, United Kingdom

LivaNova Metrics

BasicAdvanced
$2.86B
Market cap
164.45
P/E ratio
$0.32
EPS
0.94
Beta
-
Dividend rate
$2.86B
0.94418
$59.86
$42.47
629.8K
2.95
2.508
44.5
45.917
96.7
1.1%
0.75%
1.41%
0.86%
164.448
2.479
2.236
12.244
71.598
12.89%
119.96%
7.28%

What the Analysts think about LivaNova

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 9 analysts.
28.33% upside
High $82.00
Low $55.00
$52.99
Current price
$68.00
Average price target

LivaNova Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
5.25% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$310.1M
8.39%
Net income
$16.3M
-323.29%
Profit margin
5.25%
-305.88%

LivaNova Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.01%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.43
$0.78
$0.73
$0.87
-
Expected
$0.39
$0.54
$0.64
$0.77
$0.49
Surprise
9.53%
44.61%
14.78%
13.01%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for LivaNova stock?

LivaNova (LIVN) has a market cap of $2.86B as of April 14, 2024.

What is the P/E ratio for LivaNova stock?

The price to earnings (P/E) ratio for LivaNova (LIVN) stock is 164.45 as of April 14, 2024.

Does LivaNova stock pay dividends?

No, LivaNova (LIVN) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next LivaNova dividend payment date?

LivaNova (LIVN) stock does not pay dividends to its shareholders.

What is the beta indicator for LivaNova?

LivaNova (LIVN) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the LivaNova stock price target?

The target price for LivaNova (LIVN) stock is $68, which is 28.33% above the current price of $52.99. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell LivaNova stock

Buy or sell LivaNova stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing